prnewswire.com
Neutralwww.prnewswire.com ·
ascletis to present data on multiple programs at the 33rd european congress on obesity eco 2026 302762737
TAX_DISEASE_DISEASESUNGP_HEALTHCARETAX_DISEASE_OBESETAX_WORLDMAMMALS_MOUSE
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe news is a clinical data presentation announcement by Ascletis Pharma, a biotech company. The data is preclinical or early-stage (Phase I), so no immediate commercial mechanism is triggered. The potential impact is on the obesity drug market, but the data is too early to affect supply chains, product prices, or company margins. No concrete investment, regulatory, or supply chain event is reported.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Ascletis Pharma Inc. will present data at ECO 2026 in Istanbul, May 12-15, 2026.
- Phase I data for ASC47 showed up to 111.8% greater weight loss when combined with semaglutide.
- Preclinical data for ASC36 showed 32-day half-life and 91% more weight loss than petrelintide.
- ASC35, a GLP-1R/GIPR dual agonist, showed 14-day half-life and 71% more weight loss than tirzepatide.